PTC
EW icon

Philadelphia Trust Company’s Edwards Lifesciences EW Stock Holding History

Philadelphia Trust Company’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-48,966
Closed -$1.53M – 213
2017
Q1 		$1.53M Buy
+48,966
New +$1.53M 0.13% 106
2016
Q4 		– Sell
-10,350
Closed -$416K – 209
2016
Q3 		$416K Sell
10,350
-183,525
-95% -$6.91M 0.04% 162
2016
Q2 		$6.45M Buy
+193,875
New +$6.63M 0.56% 50

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Philadelphia Trust Company's EW Position: Q2 2017 in Review

Philadelphia Trust Company sold out of Edwards Lifesciences (EW) in Q2 2017, closing a stake of 48,966 shares — an estimated $1.53M sold.

Philadelphia Trust Company first reported a position in EW in Q2 2016 and held it in 3 quarters. The position peaked at $6.45M in Q2 2016. 720 funds tracked by Wall St. Rank hold EW as of Q2 2017.

  • Philadelphia Trust Company reported no remaining Edwards Lifesciences position as of Q2 2017 after selling out during the quarter.
  • Philadelphia Trust Company sold 48,966 Edwards Lifesciences shares in Q2 2017, an estimated $1.53M.
  • Philadelphia Trust Company first reported a position in Edwards Lifesciences in Q2 2016 and held it in 3 quarters.
  • Philadelphia Trust Company's Edwards Lifesciences position peaked at $6.45M in Q2 2016.
  • 720 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2017.

Based on Philadelphia Trust Company's 13F filing for Q2 2017, filed 14 Aug 2017.